Giovanni Palladini

Oct 3, 2024 | onlinelibrary.wiley.com | Mario Nuvolone |Giovanni Palladini

In their paper, the authors from the Boston University Amyloidosis Center investigate the factors that can hinder the recovery from organ compromise in light chain (AL) amyloidosis.1 This disease, the prototype of monoclonal gammopathies of clinical significance, arises when a typically small B-cell or plasma cell clone produces patient-specific, unstable, amyloid forming light chains (LCs) that deposit in tissues and lead to organ dysfunction and damage.

Jun 6, 2024 | onlinelibrary.wiley.com | Giovanni Palladini |Paolo Milani

In their paper the authors from the United Kingdom National Amyloidosis Center (NAC) show that patients with light chain (AL) amyloidosis who fail to respond to or relapse after cyclophosphamide, bortezomib and dexamethasone (VCD) can be effectively rescued with the combination of daratumumab, bortezomib and dexamethasone (DVD).